Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Denise Scots-Knight, PhD. Her UK-based company, Mereo BioPharma, is developing a therapy for alpha-1 antitrypsin deficiency (AATD).

Read the full story here: Mereo BioPharma Plans Phase 3 Study of Alvelestat for Treatment of Severe AATD

Explore more great content on Alpha-1 Antitrypsin Deficiency (AATD) →
Inhaled Therapy Could Transform AATD Treatment Landscape
Screening for Alpha-1 Antitrypsin Deficiency Presents Challenges
Favorable Outcomes Seen With Lung and Liver Transplantation in AATD
Continue Reading

alvelestat Mereo BioPharma Pulmonologists